Company: BDRX
Filing Date: 2025-11-24
Form Type: 424B3
Source: 0001214659-25-017135
Chunk: 27

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-24
Form: 424B3
Chunk 27
---
 exceed 9.99%,
provided that any increase in the beneficial ownership limitation shall not be effective until 61 days following notice to us. Beneficial
ownership of the holder and its affiliates will be determined in accordance with Section 13(d) of the Exchange Act, and the rules and
regulations promulgated thereunder.

Stock dividends and stock splits. If we pay a stock dividend or otherwise make a distribution payable in Depositary Shares or Ordinary Shares, or any other
equity or equivalent securities, subdivide or combine outstanding Depositary Shares or Ordinary Shares, or reclassify Depositary Shares,
Ordinary Shares or any shares of our capital stock, the exercise price of each February Placement Agent Warrant will be adjusted by multiplying
the then exercise price by a fraction, the numerator of which shall be the number of Depositary Shares (excluding treasury shares, if
any) outstanding immediately before such event, and the denominator of which shall be the number of Depositary Shares outstanding immediately
after such event.

Rights Offerings; pro rata distributions. If we issue Ordinary Share equivalents or rights to purchase shares, warrants, securities or other
property pro rata to holders of Depositary Shares, a holder of a February Placement Agent Warrant will be entitled to acquire, subject
to the beneficial ownership limitation described above, such securities or property that such holder could have acquired if such holder
had held the number of Depositary Shares issuable upon complete exercise of the February Placement Agent Warrant immediately prior to
the date a record is taken for such issuance. If we declare or make any dividend or other distribution of assets or rights to acquire
assets to holders of Depositary Shares or Ordinary Shares, a holder of a February Placement Agent Warrant will be entitled to participate,
subject to the beneficial ownership limitation, in such distribution to the same extent that the holder would have participated therein
if the holder had held the number of Depositary Shares issuable upon full exercise of the February Placement Agent Warrant.

Fundamental Transaction. If we effect a fundamental transaction, including, among other things, a merger, sale of substantially all of our assets,
tender offer, exchange offer and other business combination transactions, then upon any subsequent exercise of a February Placement Agent
Warrant, the holder thereof shall have the right to receive, for each Ordinary Share represented by the Depositary Shares that would have
been issuable upon such exercise immediately prior to the occurrence of such fundamental transaction, the number of shares of the successor’s
or acquiring corporation’s